Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03912064
Title	A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Dana-Farber Cancer Institute
Indications	acute myeloid leukemia myelofibrosis myelodysplastic syndrome chronic myelomonocytic leukemia myelodysplastic/myeloproliferative neoplasm
Therapies	Ipilimumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Brigham and Women's Hospital		Boston	Massachusetts	02115	United States	Details
Dana Farber Cancer Institute		Boston	Massachusetts	02115	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field